The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Abstract
High Resolution Image Download MS PowerPoint Slide KRAS G12C has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-“undruggable” target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRAS G12C to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRAS G12C inhibitor currently in phase I clinical trials (NCT03600883).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike the KRAS G12C oncoprotein, which can be successfully inhibited by covalent inhibitors targeting the mutated cysteine residue, 2,3 KRAS G12D lacks a reactive residue near the switch-II-binding pocket, making the development of covalent inhibitors challenging. 1”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [3]
In the citing paper
“For instance, AMG510 (sotorasib), the first marketed KRAS inhibitor that was granted accelerated approval (Lumakras™, Amgen, Inc.) by the FDA, is a covalent allosteric inhibitor of KRASG12C mutant, highlighting the significance of rational design of covalent allosteric drugs.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [55]
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Self-citationRAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Basic terminology of stereochemistry (IUPAC Recommendations 1996)
Moss, G. P. (1996) · Pure and Applied Chemistry · doi:10.1351/pac199668122193 · Cited by 883
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
LaPlante, S. R., Fader, L. D., Fandrick, K. R., Fandrick, D. R., Hucke, O., Kemper, R., Miller, S. P. F., & Edwards, P. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200584g · Cited by 861
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Self-citationRezai, T., Bock, J. E., Zhou, M. V., Kalyanaraman, C., Lokey, R. S., & Jacobson, M. P. (2006) · Journal of the American Chemical Society · doi:10.1021/ja063076p · Cited by 416
Research works printed but not linked: 2
- 10.1016/j.cell.2018.01.006 · DOI · Paper page
- Atropisomer interconversion was monitored by 1 H NMR. Exchange rates were calculated from line-shape analysis, coalescence temperatures, or half-lives. Free energy barriers (Δ G ⧧ ) were calculated from exchange rates using Eyring’s equation. For details, see Claridge, T. D. W. High-Resolution NMR Techniques in Organic Chemistry , 3rd ed. Elsevier: Amsterdam, The Netherlands, 2016; p 50.
Cited by
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
Subbaiah, M. A. M., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01215 · Cited by 710
Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527
Ertl, P., Altmann, E., & McKenna, J. M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00754 · Cited by 429
Metadata
- Authors
- Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., Kopecky, D. J., Liu, L., Lopez, P., Low, J. D., Ma, V., Minatti, A. E., Nguyen, T. T., Nishimura, N., Pickrell, A. J., Reed, A. B., Shin, Y., Siegmund, A. C., Tamayo, N. A., Tegley, C. M., Walton, M. C., Wang, H.-L., Wurz, R. P., Xue, M., Yang, K. C., Achanta, P., Bartberger, M. D., Canon, J., Hollis, L. S., McCarter, J. D., Mohr, C., Rex, K., Saiki, A. Y., San Miguel, T., Volak, L. P., Wang, K. H., Whittington, D. A., Zech, S. G., Lipford, J. R., & Cee, V. J.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Lanman, Brian A.
- ORCID
- Lanman, Brian A.
- Allen, Jennifer R.
- Allen, John G.
- Chen, Jian Jeffrey
- Liu, Longbin
- Lopez, Patricia
- Minatti, Ana E.
- Reed, Anthony B.
- Shin, Youngsook
- Tamayo, Nuria A.
- Wang, Hui-Ling
- Wurz, Ryan P.
- Yang, Kevin C.
- Bartberger, Michael D.
- Canon, Jude
- Rex, Karen
- Saiki, Anne Y.
- Volak, Laurie P.
- Wang, Kevin H.
- Whittington, Douglas A.
- Cee, Victor J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-12-10
- Volume
- 63
- Issue
- 1
- Pages
- 52-65
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4231423004
- Cited by
- 765
- References
- 18
- Citations by year
- 2026: 121 · 2025: 138 · 2024: 141 · 2023: 141 · 2022: 117 · 2021: 69 · 2020: 38
- FWCI
- 19.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C, covalent inhibitors, sotorasib, quinazolinone derivatives, structure-based drug design, axially chiral biaryls, configurational stability, cryptic pocket, solid tumors, undruggable targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b01180
- The paper
- Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., Kopecky, D. J., Liu, L., Lopez, P., Low, J. D., Ma, V., Minatti, A. E., Nguyen, T. T., Nishimura, N., Pickrell, A. J., . . . Cee, V. J. (2020). Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b01180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.